Table 2.
Medication Use Before and During the Study
| Gimsilumab (N = 113) | Placebo (N = 112) | |
|---|---|---|
| Before study* | ||
| Systemic corticosteroids, n (%) | 22 (19.5) | 29 (25.9) |
| Dexamethasone or dexamethasone sodium phosphate | 16 (14.2) | 10 (8.9) |
| Methylprednisolone or methylprednisolone sodium succinate | 8 (7.1) | 19 (17.0) |
| Prednisone | 3 (2.7) | 7 (6.3) |
| Remdesivir, n (%) | 34 (30.1) | 28 (25.0) |
| Azithromycin, n (%) | 41 (36.3) | 35 (31.3) |
| Hydroxychloroquine, n (%) | 5 (4.4) | 6 (5.4) |
| Immunosuppressants, n (%) | 5 (4.4) | 6 (5.4) |
| Convalescent plasma, n (%) | 3 (2.7) | 1 (0.9) |
| During study | ||
| Received Day 8 gimsilumab or placebo dose, n (%) | 63 (55.8) | 59 (52.7) |
| At least one concomitant medication | 113 (100.0) | 112 (100.0) |
| Systemic corticosteroids, n (%) | 93 (82.3) | 104 (92.9) |
| Dexamethasone or dexamethasone sodium phosphate | 60 (53.1) | 58 (51.8) |
| Methylprednisolone or methylprednisolone sodium succinate | 39 (34.5) | 43 (38.4) |
| Prednisone | 18 (15.9) | 24 (21.4) |
| Antithrombotic agents, n (%) | 110 (97.3) | 111 (99.1) |
| Remdesivir, n (%) | 55 (48.7) | 59 (52.7) |
| Azithromycin, n (%) | 30 (26.5) | 43 (38.4) |
| Immunosuppressants, n (%) | 17 (15.0) | 19 (17.0) |
| Immunoglobulin, n (%) | 13 (11.5) | 15 (13.4) |
| Hydroxychloroquine, n (%) | 4 (3.5) | 5 (4.5) |
| Convalescent plasma, n (%) | 0 (0) | 1 (0.9) |
| Prohibited medications, n (%) | 11 (9.7) | 10 (8.9) |
| Anakinra | 3 (2.7) | 5 (4.5) |
| Eculizumab | 1 (0.9) | 0 (0) |
| Filgrastim | 0 (0) | 1 (0.9) |
| Mesenchymal stem cells | 1 (0.9) | 0 (0) |
| Tocilizumab | 8 (7.1) | 9 (8.0) |
*
Started and stopped before the first dose of the study drug.